Lung Cancer

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Experts review a patient scenario of metastatic non-squamous NSCLC and discuss complexities and challenges of initiating timely molecular testing, examining its impact on treatment decisions and patient outcomes.

Explore the dynamic landscape of metastatic non-squamous non-small cell lung cancer treatment, focusing on molecular genotyping, targeted therapies, and the evolving standard of care.

A supplemental biologics license application seeking the approval of amivantamab in combination with platinum-based chemotherapy for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 19 deletions has been submitted to the FDA.

Benjamin Solomon, MBBS, PhD, FRACP, presents key data from the ALINA study investigating alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

China’s National Medical Products Administration has granted conditional marketing approval to vebreltinib for the treatment of patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Vamsidhar Velcheti, MD, discusses the significance of the FDA approval of the ROS1 TKI repotrectinib in patients with ROS1-positive metastatic non–small cell lung cancer.

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Hossein Borghaei, DO, MS, discusses the importance of determining the most suitable treatment for patients with non–small cell lung cancer through the use of biomarker testing.

Stephen V. Liu, MD, discusses the benefits of conducting biomarker testing for patients with advanced non–small cell lung cancer and highlights the importance of waiting for the results before selecting a targeted treatment.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of subcutaneous atezolizumab for all indications in which the intravenous formulation is approved, including certain types of lung, liver, bladder, and breast cancer

Concurrent administration of durvalumab and platinum-based chemoradiation failed to significantly improve progression-free survival over chemoradiation alone in patients with unresectable stage III non–small cell lung cancer, missing the primary end point of the phase 3 PACIFIC-2 trial.

After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.

Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.

Ongoing research evaluating combination therapies for the frontline treatment of patients with EGFR-mutated non–small cell lung cancer could help improve survival outcomes for this patient population.

Nicholas C. Rohs, MD, delves into the details of the case study a patient who had a lung cancer relapse detected following a referral to a dermatologist due to pityriasis rubra pilaris.

Benjamin Besse, MD, PhD, discusses the results from the ATALANTE-1 trial and details the mechanism of action of the OSE2101 vaccine.

Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.

Nicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.

Benjamin Philip Levy, MD, discusses antibody-drug conjugates under investigation in patients with non–small cell lung cancer.

While there are considerable barriers to incorporating comprehensive genotyping, the use of circulating tumor DNA offers an improvement in molecular testing—and doing so earlier can accelerate the time to treatment and improve survival for patients with lung cancer.

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.